83 results on '"Drayson, Mark T"'
Search Results
2. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
3. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
4. Free light chains as an emerging biomarker in saliva: Biological variability and comparisons with salivary IgA and steroid hormones
5. Selective effects of acute low-grade inflammation on human visual attention
6. Loneliness in healthy young adults predicts inflammatory responsiveness to a mild immune challenge in vivo
7. Low-grade inflammation decreases emotion recognition – Evidence from the vaccination model of inflammation
8. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
9. Underlying inflammation has no impact on the oxidative stress response to acute mental stress
10. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
11. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden
12. Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation
13. Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial
14. Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial
15. How I treat monoclonal gammopathy of renal significance (MGRS)
16. The time course of the inflammatory response to the Salmonella typhi vaccination
17. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
18. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
19. Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma
20. Latent Cytomegalovirus infection amplifies CD8 T-lymphocyte mobilisation and egress in response to exercise
21. Exercise intensity does not influence the efficacy of eccentric exercise as a behavioural adjuvant to vaccination
22. Phenotypic characterization of γδ T cells mobilized in response to acute psychological stress
23. The effects of vaccine timing on the efficacy of an acute eccentric exercise intervention on the immune response to an influenza vaccine in young adults
24. Mobilization of γδ T lymphocytes in response to psychological stress, exercise, and β-agonist infusion
25. Acute exercise mobilises CD8+ T lymphocytes exhibiting an effector-memory phenotype
26. Parental caregivers of children with developmental disabilities mount a poor antibody response to pneumococcal vaccination
27. The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial
28. Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis
29. The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma
30. The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
31. Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial
32. Subclonal TP53 copy number is associated with prognosis in multiple myeloma
33. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells
34. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
35. Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial
36. Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma
37. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
38. Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
39. Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)
40. Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV
41. Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min
42. Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance
43. Diffuse Large B Cell Lymphoma (DLBCL)-Released NM23-H1 Promotes Monocyte Survival and Inflammatory Cytokine Release: A Mechanistic Link between the Dual Impacts of NM23-H1 Expression and Reduced Lymphocyte:Monocyte Ratio in DLBCL Prognosis
44. The impact of response on bone-directed therapy in patients with multiple myeloma
45. Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018
46. Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial
47. Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients
48. Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial
49. Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial
50. Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.